earnings
confidence high
sentiment positive
materiality 0.85
Trevi Q2 net loss $12.3M; positive Phase 2b CORAL results for Haduvio in IPF cough
Trevi Therapeutics, Inc.
2025-Q2 EPS reported
-$0.18
- Haduvio met primary endpoint with 60.2% cough reduction (108 mg BID) vs 16.9% placebo (p<0.0001).
- LCQ Total Score increased 3.4 points (108 mg) and 3.7 points (54 mg); 1.3-point increase is clinically meaningful.
- Completed $115M underwritten offering; cash and securities $203.9M, runway into 2029.
- R&D expenses $9.4M (down from $10.0M); G&A $4.3M (up from $3.3M); net loss $12.3M.
- Plans to request End-of-Phase 2 meeting with FDA in Q4 2025; Phase 3 start expected H1 2026.